Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267

1.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, Loening T, Pantel K.

J Cancer Res Clin Oncol. 2011 Feb;137(2):261-9. doi: 10.1007/s00432-010-0881-0. Epub 2010 Apr 16.

PMID:
20396915
2.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

4.

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.

Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J.

Br J Cancer. 2003 May 19;88(10):1587-91.

5.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
7.

Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.

Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli AM, Merola R, Donnorso RP, Sperduti I, Buglioni S, Mottolese M.

Oncologist. 2006 Sep;11(8):878-86.

8.
9.
10.

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M.

Breast. 2006 Aug;15(4):519-27. Epub 2005 Nov 14.

PMID:
16290155
11.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
12.

HER2 gene amplification in patients with breast cancer with equivocal IHC results.

Meijer SL, Wesseling J, Smit VT, Nederlof PM, Hooijer GK, Ruijter H, Arends JW, Kliffen M, van Gorp JM, Sterk L, van de Vijver MJ.

J Clin Pathol. 2011 Dec;64(12):1069-72. doi: 10.1136/jclinpath-2011-200019. Epub 2011 Aug 11.

PMID:
21836036
13.
14.

Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.

Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.

Exp Mol Pathol. 2007 Jun;82(3):262-8. Epub 2007 Jan 30.

PMID:
17335803
15.
16.
17.

Emerging technologies for assessing HER2 amplification.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.

Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Review.

PMID:
19762531
18.

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.

Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.

PMID:
23121603
19.
20.

Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.

Mehrazma M, Kalantari E, Rezvani H, Bahar B, Basi A, Razavi SM, Rakhshani N.

Asian Pac J Cancer Prev. 2015;16(17):7695-700.

Supplemental Content

Support Center